NanoViricides (NYSE American:NNVC) has announced that it has signed a broad memorandum of understanding agreement granting it the right of first refusal (ROFR) for all antiviral drug developments, including trojan horse drugs, from the research and development company, TheraCour Pharma.
The company reports that discussions surrounding the agreement were led by its board of directors and represent an important step toward further developing multiple drug candidates for antiviral applications, many of which have previously been considered to be intractable.
NanoViricides maintains that nanoviricide technology, which results in host-mimetic, direct-acting antiviral drugs, is ushering in a new era for the treatment of viral infections, much like penicillin revolutionized the treatment of bacterial infections. This technology enables a “one drug – many bugs” model as opposed to the current “one bug – one drug” model.
The company’s NV-387 exemplifies the capabilities of nanoviricide technology, which was developed in 2020 in response to the COVID-19 pandemic and has successfully completed a Phase I clinical trial. NanoViricides is currently planning Phase II clinical trials to evaluate the efficacy of NV-387 against several viral diseases, including RSV, Influenza, Bird Flu, COVID, as well as MPOX/Smallpox infections.
